We summarize here in vitro evidences of efficacy for convalescent plasma, currently approved vaccines and monoclonal antibodies against SARS-CoV-2 variants of concern (VOC: B.1.1.7, B.1.351, P.1, and B.1.617.2), variants of interest (VOI: B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.671.1), and other strains (B.1.1.298 and B.1.258delta). While waiting from real world clinical efficacy, these data provide guidance for the treating physician.
All Keywords
【저자키워드】 COVID-19, convalescent plasma, neutralizing antibody, SARS-CoV-2, mutations, Immune escape, Imdevimab, etesevimab, REGN10987, LyCoV016, 【초록키워드】 Efficacy, Vaccine, B.1.351, monoclonal antibody, SARS-CoV-2 variant, B.1.617.2, in vitro, B.1.1.7, P.1, P.2, variants of interest, B.1.526, Guidance, Evidence, Clinical efficacy, strain, These data, B.1.525, while, approved,
【저자키워드】 COVID-19, convalescent plasma, neutralizing antibody, SARS-CoV-2, mutations, Immune escape, Imdevimab, etesevimab, REGN10987, LyCoV016, 【초록키워드】 Efficacy, Vaccine, B.1.351, monoclonal antibody, SARS-CoV-2 variant, B.1.617.2, in vitro, B.1.1.7, P.1, P.2, variants of interest, B.1.526, Guidance, Evidence, Clinical efficacy, strain, These data, B.1.525, while, approved,